Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
2008
2009
2010
Announcements
Articles
Articles and Publications
Campaign
Case Studies
Charge Capture and Pricing
Coding Integrity
Company
Craneware Insights Articles
Directors
Education
Home
Journey
Opportunities
Other
post
Press Releases
Products
Testimonial
Trade Shows
Uncategorized
Upcoming Events
Webinars
White Papers

New Claims Monitoring Policy for EPO/Aranesp

About Craneware Insights


Craneware Insights Articles communicate important regulatory changes to Medicare Outpatient billing, Chargemaster (CDM) and coding compliance. Craneware analyzes Transmittals and bulletins from the Centers for Medicare and Medicaid Services (CMS) and other organizations such as Recovery Audit Contractors (RACs) and emails Insights Articles in a focused manner to alert customers to pertinent regulatory changes.

Regulatory News Topic


Change Request (?CR?) 4135 released November 10, 2005, announces a new national monitoring policy for erythropoietin and darbepoetin (EPO and Aranesp) for ESRD patients treated in renal dialysis facilities. The intent of this policy is to ensure that EPO and Aranesp are not over-utilized in the treatment of the Medicare ESRD in-facility population.

Date of Insight Article


Friday, November 11, 2005

What you need to know and action needed


To view this complete Insights Article including detailed breakdown of Provider Types Affected, Departments Affected, What You Need to Know, Action Needed and Background and Reference links, customers may sign onto Craneware Online Reference Toolkit?.